TCU’s Cannon Diagnosed with Non-Hodgkin’s Lymphoma

According to multiple reports, former TCU offensive tackle Marcus Gannon will begin chemotherapy at a Fort Worth hospital on Thursday for a form of non-Hodgkin’s lymphoma. Cannon, of course, had been deemed a potential first or second round pick in the upcoming 2011 NFL Draft, and was considered to be one of the premiere talents available at his position.

While murmurs that all was not well with Cannon’s health had been circulating amongst teams, it’s difficult to say how many really knew that he was dealing with this particular condition. Either way, it’s all but guaranteed at this point that the TCU product will drop in the draft -- the question now being how much.

Apparently, the tumor was first detected in Cannon’s abdomen in 2006. However, testing on it showed that it was benign. Later, in 2008, further testing on it still returned negative.

Finally, after the mass grew during the NFL Scouting Combine in February, rumors began to circulate that Cannon was battling testicular cancer. Ultimately, that rumor was proven to be incorrect.

In an effort to keep teams fully apprised of the situation, each NFL team was sent full biopsy results to prove that Cannon was not suffering from testicular cancer. The tests, however, did show that he was suffering from the aforementioned non-Hodgkin’s lymphoma.

Cannon’s four treatments are set to conclude on June 29.

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap